Measurement of Cytokines in Clinical Samples Using Immunoassays: Problems and Pitfalls
- 1 January 2000
- journal article
- review article
- Published by Taylor & Francis in Critical Reviews in Clinical Laboratory Sciences
- Vol. 37 (2) , 131-182
- https://doi.org/10.1080/10408360091174187
Abstract
With the explosion in interest in cytokines and an increasing understanding of their possible involvement in the pathogenesis of many diseases, the number of studies measuring cytokines in body fluids has increased markedly over the last 5 to 10 years. However, it is readily apparent from the literature that the level of awareness of the many factors that can potentially influence the results obtained is very low. Such factors are likely to contribute considerably to the disparities seen among similar types of study. These include assay properties such as standardization and specificity, type of sample and sample handling, and many biological influences such as age, sex, ethnic background, and diurnal rhythmicity. Clearly, it is not possible to control for all these factors, but a minimum evaluation of assays should be carried out as described, including recovery and parallelity studies using relevant samples and the establishment of reproducibility and normal healthy population levels. An awareness of these factors, which is the purpose of this review, may hopefully lead to an improvement in the quality of studies incorporating the measurement of cytokines in clinical samples and should aid in the interpretation of the data.Keywords
This publication has 297 references indexed in Scilit:
- CorrespondenceEuropean Journal Of Cancer, 1998
- Pharmacokinetic Studies with Recombinant CytokinesClinical Pharmacokinetics, 1997
- The development of anti-interleukin-2 (IL-2) antibodies in cancer patients treated with recombinant IL-2European Journal Of Cancer, 1994
- Seasonal variation in peripheral blood leukocyte subsets and in serum interleukin-6, and soluble interleukin-2 and-6 receptor concentrations in normal volunteersCellular and Molecular Life Sciences, 1994
- Circadian rhythm of serum interleukin-6 in rheumatoid arthritis.Annals of the Rheumatic Diseases, 1994
- Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation.The Journal of Experimental Medicine, 1993
- Transforming growth factor‐β1 is a heparin‐binding protein: Identification of putative heparin‐binding regions and isolation of heparins with varying affinity for TGF‐β1Journal of Cellular Physiology, 1992
- Increase of plasma IL-6 concentration with age in healthy subjectsLife Sciences, 1992
- In-vitro production of TNF-α in blood samplesThe Lancet, 1990
- Renal Filtration, Absorption and Catabolism of Human Alpha InterferonJournal of Interferon Research, 1981